Reviewer’s report

Title: Safety and efficacy of vemurafenib in end stage renal failure.

Version: 1 Date: 9 October 2013

Reviewer: Mori Krantz

Reviewer’s report:

Major compulsory revisions
please provide a rationale for attribution of drug induced QTC when there was a history of such fluctuation 2 years prior?
Use a validated probability score such as Naranjo et al for attribution; you will see that the association is not strong
Show twelve lead ECGs so the reader can understand morphology and ascertain if the patient had congenital LQTS

Level of interest: An article of limited interest

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

none